Anti Alpp Car-T Cells Treatment
Recurrent or Metastatic Solid Tumors With Positive ALPP
Haifeng QinCell therapyEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Recurrent or Metastatic Solid Tumors With Positive ALPP cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Haifeng Qin | Early Phase 1 | C |
Fludarabine Haifeng Qin | Early Phase 1 | C |
Same molecule, other indications
Anti Alpp Car-T Cells Treatment is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →